O'Brien Greene & Co’s Boston Scientific BSX Stock Holding History

O'Brien Greene & Co’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.23M	Buy	+83,406	New	+$6.67M	1.48%	24

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

O'Brien Greene & Co's BSX Position: Q1 2026 in Review

O'Brien Greene & Co opened a new position in Boston Scientific (BSX) in Q1 2026: 83,406 shares worth $5.23M. The stake represents 1.48% of the portfolio and ranks #24 among its holdings.

1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

O'Brien Greene & Co held 83,406 shares of Boston Scientific worth $5.23M as of Q1 2026.
Boston Scientific was a new O'Brien Greene & Co position in Q1 2026.
Boston Scientific made up 1.48% of O'Brien Greene & Co's portfolio in Q1 2026, its #24 holding.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on O'Brien Greene & Co's 13F filing for Q1 2026, filed 6 May 2026.